This article was downloaded by:


On: 27 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-

41 Mortimer Street, London W1T 3JH, UK



## Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information: <a href="http://www.informaworld.com/smpp/title~content=t713597286">http://www.informaworld.com/smpp/title~content=t713597286</a>

# HIV Inhibition by Antisense Oligodeoxynucleotides

M. Mag<sup>a</sup>; J. Muth<sup>a</sup>; S. Lücking<sup>a</sup>; L. Biesert<sup>b</sup>; J. Engels<sup>a</sup>

<sup>a</sup> Institut für Organische Chemie, Johann Wolfgang Goethe-Universitat, <sup>b</sup> Chemothera-peutisches Institut Georg Speyer-Haus,

To cite this Article Mag, M., Muth, J., Lücking, S., Biesert, L. and Engels, J.(1991) 'HIV Inhibition by Antisense Oligodeoxynucleotides', Nucleosides, Nucleotides and Nucleic Acids, 10: 1, 627 - 629

To link to this Article: DOI: 10.1080/07328319108046553 URL: http://dx.doi.org/10.1080/07328319108046553

## PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

#### HIV INHIBITION BY ANTISENSE OLIGODEOXYNUCLEOTIDES

M. Mag, J. Muth, S. Lücking, L. Biesert\* and J. Engels\*
\*Institut für Organische Chemie, Johann Wolfgang Goethe-Universität,
Niederurseler Hang, D-6000 Frankfurt am Main 50 and \*Chemotherapeutisches Institut Georg Speyer-Haus, D-6000 Frankfurt am Main 70

## **ABSTRACT**

A series of oligodeoxynucleotides containing phosphorothicates and normal internucleotide linkages were synthesized and tested for their antiviral activity against HIV 1.

## RESULTS AND DISCUSSION

One promising approach for treatment of HIV infected patients with AIDS is to use antisense oligodeoxynucleotides (ODN) to selectively block virus replication by competitive hybridization. These ODN have to fulfill some special prerequisites such as nuclease resistance, duplex stability and cell membrane permeability. For this purpose a series of ODN containing phosphorothicates and normal internucleotide linkages were synthesized according to the phosphoramidite procedure. These include normal ODN and such which are end-capped at the 3', 5' or both 3' and 5' position. (2)

**TABLE:** Synthesized oligodeoxynucleotides; Chol.: cholesterylphosphoryl, S: phosphorothioate linkage

1	3'- ТСТ	GGG	TTA	AGA	стт	TTA	C C-5'
2	5'- A C A	ССС	AAT	TCT	GAA	AAT	G G-3'
3	5'- A C A					···A Ts	GsG-3'
4	5'- AsCsA	• • • • •	• • • • • •			···· A Ts	GsG−3'
5	5'- AsCsA		• • • • • • •			···A T	G G-3'
6	5'- A C A			• • • • • •		···· As Ts	GsG-3'
7	5'-CholA C A	• • • • • •			• • • • • •	····A T	G G-3'
8	5'-CholA C A					··· A Ts	GsG-31

628 MAG ET AL.




FIGURE: Degradation of the oligonucleotides 2-5 in RPMI 1640 medium containing 15% fetal calf serum. Silver stained 16% PAA/7M wrea gel.

The ODN were purified by HPLC and analyzed by  $^{31}P-NMR$  spectroscopy (121.5MHz.  $D_2O$ ). The spectra of 3-5 are showing a peak at 56.6ppm downfield from 85%  $H_3PO_4$  (PS-resonance) and a peak at -0.4ppm (PO-resonance). Only the 5' end-capped oligomer 5 gave the correct integrated PS/PO peak ratio whereas the spectra of 3 and 4 have shown a reduced sulfur content. This indicates that the PS-linkage is not stable under the synthesis conditions.

The end-capped ODN were tested for their resistance against fetal calf serum (15% in RPMI 1640 medium, 37°C) which always contains exonucleases. Only the 3' (3) and 3',5' (4) ODN are stable under these conditions whereas the normal (2) and 5' (5) end-capped ODN were degraded within 4-6 hours.

The melting temperatures of these end-capped ODN are nearly the same as their natural congeners (delta  $T_m\approx 2\,^{\circ}\text{C}$ ). To enhance the cell membrane permeability we have synthesized some ODN conjugated at the 5'-terminus to cholesterol(3) via a cholesterylphosphoramidite. The lipophilicity of these conjugates was extremely enhanced as observed by HPLC. Finally the antisense ODN were tested for their ability to inhibit virally induced syncytia formation in human activated lymphocytes in concentations from  $1-50\,\mu\text{g/ml}$ . As target site within the HIV 1 genome we used the splice acceptor site (5'-CCA UUU UCA GAA UUG GGU GU-3') for the tat gene. (4)

It was found that the introduction of thioates enhances the antiviral activity (greater than 85% inhibition in each case). A cholesteryl group at the 5'-terminus causes complete inhibition of syncytia formation at a concentration of 20µg ml. At low concentrations these conjugates were less active compared with the other oligonucleotides tested.

## REFERENCES

- 1) Uhlmann, E. and Peyman, A. (1990) Chemical Rev., 90, 544
- 2) Stein, C.A. et al. (1988) Nucleic Acids Res., 16, 3209
- 3) Letsinger, R.L et al. (1989) Proc.Natl.Acad.Sci.USA, 86, 6553
- 4) Goodchild, J. et al. (1988) Proc.Natl.Acad.Sci.USA, 85, 5507